84 results
6-K
EX-99.2
ORTX
Orchard Therapeutics plc
5 Nov 18
Orchard Therapeutics Announces Pricing of Initial Public Offering
7:40am
, telephone: (866) 803-9204, or by emailing prospectus-eq_fi@jpmchase.com; Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New … Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Attention: Prospectus Department, or by email at PostSaleManualRequest
6-K
EX-99.1
ORTX
Orchard Therapeutics plc
5 Nov 18
Orchard Therapeutics Announces Pricing of Initial Public Offering
7:40am
, or by emailingprospectus-eq_fi@jpmchase.com; Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, New York 10282, telephone:866 … Avenue, Edgewood, New York 11717, Attention: Prospectus Department, or by email at PostSaleManualRequest@broadridge.com.
This press release shall
6-K
EX-99.1
ORTX
Orchard Therapeutics plc
6 Jun 19
Orchard Therapeutics Launches Proposed Public Offering
4:31pm
, 1155 Long Island Avenue, Edgewood, NY 11717, telephone:866-803-9204; Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY … Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, telephone:631-274-2806 and Barclays Capital Inc., c/o Broadridge
6-K
EX-99.2
ORTX
Orchard Therapeutics plc
6 Jun 19
Orchard Therapeutics Launches Proposed Public Offering
4:31pm
Long Island Avenue, Edgewood, NY 11717, telephone:866-803-9204; Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282 … , 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, telephone:631-274-2806 and Barclays Capital Inc., c/o Broadridge Financial
8-K
EX-99.1
ORTX
Orchard Therapeutics plc
9 Jul 20
Orchard Therapeutics and MolMed Announce Extension of Gene Therapy Manufacturing Collaboration
7:03am
Department of Ospedale San Raffaele and an operating site at Bresso, at the OpenZone campus.
Availability of Other Information About Orchard
Investors … & Communications Department
MolMed S.p.A.
+39 02 21277.205
investor.relations@molmed.com
Tommasina Cazzato
Press OfficeCommunity Group+39 345 7357751
tommasina.cazzato@communitygroup.it
DEFA14C
jtcq8
5 Oct 23
Additional information
4:43pm
F-6
EX-99
khvpwitklh044k qmt
19 Oct 18
Registration for ADRs (foreign)
4:53pm
8-K
EX-99.1
m974cka0nd3b fmkwrro
5 Oct 23
Kyowa Kirin to Acquire Orchard Therapeutics
9:05am
DEFA14C
v17dc90j vg54f
5 Oct 23
Additional information
4:40pm
8-K
bln3k6y1b1q
21 Nov 23
Other Events
7:51am
8-K
8e953p54m5zh8h
30 Nov 23
Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH
4:06pm
8-K
EX-99.1
s3h37ydt2aic
13 Nov 23
Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments
7:05am
DEFA14A
y76 wmqrvm
8 Dec 23
Additional proxy soliciting materials
4:39pm
8-K
r2nnwkgdi
8 Dec 23
Other Events
4:37pm
DEFA14A
zgwh av76rsyppsbsbd1
21 Nov 23
Additional proxy soliciting materials
7:53am
8-K
EX-2.2
7y4l lpqg5
24 Jan 24
Termination of a Material Definitive Agreement
4:17pm
DEFA14A
7i551
17 Oct 23
Additional proxy soliciting materials
4:32pm
DEFA14C
hjndqxso
5 Oct 23
Additional information
5:26pm
8-K
3jrig85
13 Nov 23
Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments
7:05am